PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.

CompletedOBSERVATIONAL

Enrollment

296

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

August 31, 2021

Study Completion Date

February 17, 2022

Conditions

Contraceptive

Interventions

DRUG

Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)

Follow clinical administration

Trial Locations (1)

Many locations, Multiple Locations